A short treatment with galactomannan GM-CT-01 corrects the functions of freshly isolated human tumor-infiltrating lymphocytes

Clinical Cancer Research

Volumn 20, Issue 7, 2014, Pages 1823-1833

  Demotte, Nathalie ^a   Bigirimana, René ^a   Wieërs, Grégoire ^a,b   Stroobant, Vincent ^a   Squifflet, Jean Luc ^b   Carrasco, Javier ^d   Thielemans, Kris ^c   Baurain, Jean François ^b   Van Der Smissen, Patrick ^a   Courtoy, Pierre J ^a   Van Der Bruggen, Pierre ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c FACULTY OF MEDICINE AND PHARMACY   (Belgium)

^d Grand Hopital de Charleroi   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GALACTOMANNAN; GAMMA INTERFERON; GM CT 01; GUAR GUM; UNCLASSIFIED DRUG; GALECTIN 1; GALECTIN 3; GALECTIN-3, HUMAN; MANNAN;

ANTIGEN EXPRESSION; ARTICLE; ASCITES; CANCER IMMUNIZATION; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SAFETY; HUMAN; HUMAN CELL; INCUBATION TIME; LYMPHOCYTE FUNCTION; OVARY CARCINOMA; PRIORITY JOURNAL; SOLID TUMOR; TUMOR ASSOCIATED LEUKOCYTE; ANTAGONISTS AND INHIBITORS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASMS; PATHOLOGY;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; GALECTIN 1; GALECTIN 3; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MANNANS; NEOPLASMS;

EID: 84898759431     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2459     Document Type: Article

References (55)

1. Wieërs G, Demotte N, Godelaine D, van der Bruggen P. Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines. Cancers 2011;3:2904-54.
2. Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 2010;16:399-403.
3. Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013;31:2388-95.
4. Gajewski T, Zha Y, Thurner B, Schuler G. Association of gene expression profile in metastatic melanoma and survival to a dendritic cell-based vaccine. J Clin Oncol (2009ASCO Annual Meeting Proceedings) 2009;27 No.15S:9002.
5. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677-85. (Pubitemid 29289432)
6. + tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Eur J Immunol 1994;24:1966-73.
7. Van den Hove LE, Van Gool SW, Van Poppel H, Baert L, Coorevits L, Van Damme B, et al. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma. Clin Exp Immunol 1997;109:501-9. (Pubitemid 27402320)
8. Demotte N, Wieërs G, Van Der Smissen P, Moser M, Schmidt CW, Thielemans K, et al. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res 2010;70:7476-88.
9. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Liénard D, Lejeune F, et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004;64:2865-73. (Pubitemid 38500627)
10. + T cell dysfunction in melanoma patients. J Exp Med 2010;207:2175-86.
11. Le Drean E, Vely F, Olcese L, Cambiaggi A, Guia S, Krystal G, et al. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. Eur J Immunol 1998;28:264-76. (Pubitemid 28048297)
12. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003;100:8372-7. (Pubitemid 36842552)
13. Sedy JR, Gavrieli M, Potter KG,HurchlaMA, Lindsley RC, Hildner K, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 2005;6:90-8. (Pubitemid 40136700)
14. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
15. Betz M, Fox BS. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 1991;146:108-13.
16. Kehrl JH, Roberts AB, Wakefield LM, JakowlewS, Sporn MB,FauciAS. Transforming growth factor β is an important immunomodulatory protein for human B lymphocytes. J Immunol 1986;137:3855-60. (Pubitemid 17215314)
17. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269-74. (Pubitemid 37279849)
18. Stockis J, Fink W, François V, Connerotte T, De Smet C, Knoops L, et al. Comparison of stable human Treg and Th clones by transcriptional profiling. Eur J Immunol 2009;39:869-82.
19. + T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res 2009;69:4335-45.
20. Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007;110:2983-90. (Pubitemid 350006952)
21. Liu FT, Hsu DK, Zuberi RI, Kuwabara I, Chi EY, Henderson WRJr. Expression and function of galectin-3, a β-galactoside-binding lectin, in human monocytes and macrophages. Am J Pathol 1995;147:1016-28.
22. van Stijn CM, van den Broek M, van de Weerd R, Visser M, Tasdelen I, Tefsen B, et al. Regulation of expression and secretion of galectin-3 in human monocyte-derived dendritic cells. Mol Immunol 2009;46:3292-9.
23. Rabinovich GA, Toscano MA. Turning 'sweet' on immunity: galectinglycan interactions in immune tolerance and inflammation. Nat Rev Immunol 2009;9:338-52.
24. Demotte N, Stroobant V, Courtoy PJ, Van Der Smissen P, Colau D, Luescher IF, et al. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 2008;28:414-24. (Pubitemid 351335307)
25. Pace KE, Lee C, Stewart PL, Baum LG. Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J Immunol 1999;163:3801-11. (Pubitemid 29450905)
26. Fukumori T, Takenaka Y, Yoshii T, Kim HR, Hogan V, Inohara H, et al. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res 2003;63:8302-11. (Pubitemid 37549482)
27. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor-immune privilege. Cancer Cell 2004;5:241-51. (Pubitemid 38402116)
28. Stillman BN, Hsu DK, Pang M, Brewer CF, Johnson P, Liu FT, et al. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol 2006;176:778-89. (Pubitemid 43099674)
29. Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T cells mediated by galectin-1. Nature 1995;378:736-9. (Pubitemid 126647279)
30. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7. (Pubitemid 21917508)
31. Wilgenhof S, Van Nuffel AM, Benteyn D, Corthals J, Aerts C, Heirman C, et al. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol 2013 July 31. [Epub ahead of print].
32. Boon T, Coulie PG, Van den Eynde B, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006;24:175-208.
33. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15. (Pubitemid 39273730)
34. Lurquin C, Lethé B, Corbière V, Théate I, van Baren N, Coulie PG, et al. Contrasting frequencies of anti-tumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005;201:249-57. (Pubitemid 40189434)
35. Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron N, et al. High frequency of anti-tumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005;201:241-8. (Pubitemid 40189433)
36. Carrasco J, Van Pel A, Neyns B, Lethé B, Brasseur F, Renkvist N, et al. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J Immunol 2008;180:3585-93.
37. Miller MC, Klyosov A, Mayo KH. The a-galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain. Glycobiology 2009;19:1034-45.
38. Klyosov A, Zomer E, Platt D. DAVANAT® (GM-CT-01) and colon cancer: preclinical and clinical (phase I and II) studies. In: Klyosov AA, editor. Glycobiology and drug design (ACS symposium series, 1102). Washington, DC: American Chemical Society; 2012. p. 89-130.
39. KlyosovAA, Traber PG. Galectins in disease and potential therapeutics approaches. In: Klyosov AA, Traber PG, editors. Galectins and disease implications for targeted therapeutics (ACS symposium series, 1115). Washington, DC: American Chemical Society; 2012. p. 3-43.
40. Klyosov AA, Zomer E, Platt D. DAVANAT® and colon cancer: preclinical and clinical (phase I) studies. In:Klyosov AA, Witczak ZJ, Platt D, editors. Carbohydrate drug design (ACS symposium series, 932). Washington, DC: American Chemical Society; 2006. p. 67-104.
41. Uyttenhove C, Maryanski J, Boon T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 1983;157:1040-52. (Pubitemid 13117080)
42. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 2000;6:1389-93. (Pubitemid 30226225)
43. Eliaz I. The Role of galectin-3 as a marker of cancer and inflammation in a stage IV ovarian cancer patient with underlying pro-inflammatory comorbidities. Case Rep Oncol 2013;6:343-9.
44. Antonopoulos A, Demotte N, Stroobant V, Haslam SM, van der Bruggen P, Dell A. Loss of effector function of human cytolytic T lymphocytes is accompanied by major alterations in N- and O-glycosylation. J Biol Chem 2012;287:11240-51.
45. + T cell expansion in melanoma patients. J Immunol 2009;182:5240-9.
46. Wong RM, Scotland RR, Lau RL, Wang C, Korman AJ, Kast WM, et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol 2007;19:1223-34. (Pubitemid 47500645)
47. Miller MC, Nesmelova IV, Platt D, Klyosov A, Mayo KH. The carbohydrate-binding domain on galectin-1 is more extensive for a complex glycan than for simple saccharides: implications for galectin-glycan interactions at the cell surface. Biochem J 2009;421:211-21.
48. ., Nesmelova IV, Dings RPM, Mayo KH. Understanding galectin structure-function relationship to design effective antagonists. In:Klyosov AA, Witczak ZJ, Platt D, editors. Galectins. Hoboken, New Jersey: John Wiley & Sons; 2008. p. 33-69.
49. Fradin C, Poulain D, Jouault T. β-1,2-Linked oligomannosides from Candida albicans bind to a 32-kDa macrophage membrane protein homologous to the mammalian lectin galectin-3. Infect Immun 2000;68:4391-8. (Pubitemid 30497703)
50. Kohatsu L, Hsu DK, Jegalian AG, Liu FT, Baum LG. Galectin-3 induces death of Candida species expressing specific β-1,2-linked mannans. J Immunol 2006;177:4718-26. (Pubitemid 44469805)
51. + T lymphocytes leads to dramatic remodeling of N-linked glycans. J Immunol 2006;177:2431-40.
52. Antonopoulos A, North SJ, Haslam SM, Dell A. Glycosylation of mouse and human immune cells: insights emerging from N-glycomics analyses. Biochem Soc Trans 2011;39:1334-40.
53. Streetly MJ, Maharaj L, Joel S, Schey SA, Gribben JG, Cotter FE. GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood 2010;115:3939-48.
54. Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res 2005;65:8350-8. (Pubitemid 41330600)
55. Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res 2009;344:1788-91.